Qiagen Claims Market Leadership in HPV Testing as Molecular Dx Business Drives Q2 Revenue Growth

In a conference call to discuss its second-quarter earnings, the company told investors that it will delay the anticipated launch time of its higher throughput and fully automated QIAensemble Revolution platform for HPV and other molecular testing in an effort to make it more amenable to centralized testing labs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.